


Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-CB712ACB-21F0-4CD3-B3C2-34083D05B20B_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M27750_04_01
 DOI Ref: eh4fv

© 2025 USPC
 Do not distribute

Divalproex Sodium



$(C_{16}H_{31}NaO_4)_n$ 310.41 (repeating unit molecular weight)
 Pentanoic acid, 2-propyl-, sodium salt (2:1);
 Sodium hydrogen bis(2-propylvalerate) oligomer.

DEFINITION

Divalproex Sodium contains NLT 98.0% and NMT 102.0% of available valproic acid ($C_8H_{16}O_2$).

IDENTIFICATION

Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197K](#) ▲ (CN 1-MAY-2020)
- **B.** [IDENTIFICATION TESTS—GENERAL \(191\)](#), [Chemical Identification Tests, Sodium](#)
Sample: 100 mg of Divalproex Sodium
Analysis: Ignite the *Sample*, and dissolve the residue in 2 mL of [water](#). Proceed as indicated in the chapter, starting with “Add 2 mL”.
Acceptance criteria: Meets the requirements
- **C.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Buffer: 3.5 g of [monobasic sodium phosphate](#) in 900 mL of [water](#). Adjust with [phosphoric acid](#) to a pH of 3.5. Dilute with [water](#) to 1 L.

Mobile phase: [Acetonitrile](#) and *Buffer* (50:50)

Impurity stock solution: 0.5 mg/mL of [USP Valproic Acid Related Compound A RS](#) in [acetonitrile](#)

Standard stock solution: 5.0 mg/mL of [USP Valproic Acid RS](#) in *Mobile phase*

System suitability solution: 0.5 mg/mL of valproic acid from the *Standard stock solution*, and 5 µg/mL of valproic acid related compound A from the *Impurity stock solution* in *Mobile phase*

Standard solution: 0.5 mg/mL of [USP Valproic Acid RS](#) from the *Standard stock solution* in *Mobile phase*

Sample solution: 0.5 mg/mL of Divalproex Sodium in *Mobile phase*

Chromatographic system
 (See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 215 nm

Column: 4.6-mm × 15-cm; 5-µm packing [L7](#)

Flow rate: 1 mL/min

Injection volume: 20 µL

Run time: NLT 1.8 times the retention time of valproic acid

System suitability

Sample: *System suitability solution*

[NOTE—The relative retention times for valproic acid related compound A and valproic acid are 0.69 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 5.0 between valproic acid related compound A and valproic acid

Tailing factor: NMT 1.5 for valproic acid

Relative standard deviation: NMT 2.0% for valproic acid

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of available valproic acid ($C_8H_{16}O_2$) in the portion of Divalproex Sodium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times (1/M) \times 100$$

r_U = peak area from the *Sample solution*

r_S = peak area from the *Standard solution*

C_S = concentration of [USP Valproic Acid RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of the *Sample solution* (mg/mL)

M_{r1} = molecular weight for divalproex sodium repeating unit, 310.41

M_{r2} = molecular weight for valproic acid, 144.21

M = number of moles of valproic acid per mole of divalproex sodium repeating unit, 2

Acceptance criteria: 98.0%–102.0%

SPECIFIC TESTS

- [WATER DETERMINATION \(921\)](#), [Method I](#): NMT 1.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store at room temperature.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Divalproex Sodium RS](#)

[USP Valproic Acid RS](#)

[USP Valproic Acid Related Compound A RS](#)

Diallyl acetic acid;

Also known as 2-Allylpent-4-enoic acid.

$C_8H_{12}O_2$ 140.18

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DIVALPROEX SODIUM	Documentary Standards Support	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 42(5)

Current DocID: [GUID-CB712ACB-21F0-4CD3-B3C2-34083D05B20B_4_en-US](#)

DOI: https://doi.org/10.31003/USPNE_M27750_04_01

DOI ref: [eh4fv](#)